Cancer Microbiome Market Report and Forecast 2025-2034
Description
The global cancer microbiome market size was valued at USD 267.14 Million in 2024, driven by the increasing prevalence of chronic cancers across the globe. The market size is anticipated to grow at a CAGR of 19.90% during the forecast period of 2025-2034 to achieve a value of USD 1640.33 Million by 2034.
Cancer Microbiome: Introduction
Microbiome refers to the population of microorganisms, including bacteria, viruses, and fungi, that exist in the human body. Cancer microbiomes, also known as tumor microbiomes, are a group of microorganisms that live in and around cancerous tumors in the human body. These microorganisms can either promote or inhibit tumor growth, depending on their effects on cancer.
The cancer microbiome offers several advantages, including the potential to gain insights into the development and spread of cancer. This understanding could help in devising strategies to prevent cancer progression or metastasis. By identifying specific microbes that either stimulate or hinder tumor growth, targeted therapies could also be developed.
Global Cancer Microbiome Market Analysis
The increasing number of clinical studies to explore the potential of microbiomes in managing responses against cancer treatments are acting as a major trend for the global cancer microbiome market growth in the coming years. For example, a study was published in the Journal of Clinical Oncology studying the microbiomes with advanced biliary tract cancer to observe their response against a new treatment that combines durvalumab with cisplatin and gemcitabine.
The growing demand for personalized medicine worldwide is driving the global market for cancer microbiome further. The increasing number of research and development activities and increasing collaborations between the microbiome industry and academia to utilize the resources and expertise of both are likely to add significant growth to the overall global cancer microbiome market share.
In addition, increasing collaboration between key players and innovative companies to develop transformative advancements is also expected to drive the market growth. For example, The University of Texas MD Anderson Cancer Centre and Federation Bio have partnered to create a synthetic microbial consortium, which aims to expand the number of cancer patients responding to immunotherapy.
Key biotech companies are also raising funds from investors interested in the development of new cancer treatments with the help of microbiome potential. For instance, Enterome, a biotech company, aims to raise USD 108 million for its clinical studies and support clinical trials, including two Phase II studies.
Pragma Bio has also raised a whopping USD 10 million in funding. The startup aims to initiate the first part of a 10-year plan. Pragma is using artificial intelligence to create a statistical model that identifies potential candidates for microbiome investigation. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with the microbiome. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with microbiome.
Global Cancer Microbiome Market Segmentations
Cancer Microbiome Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
The increasing prevalence of chronic cancers across the globe is a major factor driving the growth of the market. The increasing demand for personalized cancer treatments is also influencing the market growth. The increasing use of genome sequencing in exploring the potential of microbiome in cancer treatments, as it helps researchers to analyze the composition of microbial communities in and around cancerous tissues, is also expected to drive the market growth. The continuous advancements in research and development activities also act as a major factor driving the global cancer microbiome market growth.
The market development is also driven by the heavy investments by pharmaceutical companies, government agencies, and private investors, in microbiome research for cancer and the development of new therapies and products. The increased number of clinical trials to explore and create microbiome-based treatments for cancer is gaining popularity in the market, further propelling the market growth.
Global Cancer Microbiome Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Cancer Microbiome: Introduction
Microbiome refers to the population of microorganisms, including bacteria, viruses, and fungi, that exist in the human body. Cancer microbiomes, also known as tumor microbiomes, are a group of microorganisms that live in and around cancerous tumors in the human body. These microorganisms can either promote or inhibit tumor growth, depending on their effects on cancer.
The cancer microbiome offers several advantages, including the potential to gain insights into the development and spread of cancer. This understanding could help in devising strategies to prevent cancer progression or metastasis. By identifying specific microbes that either stimulate or hinder tumor growth, targeted therapies could also be developed.
Global Cancer Microbiome Market Analysis
The increasing number of clinical studies to explore the potential of microbiomes in managing responses against cancer treatments are acting as a major trend for the global cancer microbiome market growth in the coming years. For example, a study was published in the Journal of Clinical Oncology studying the microbiomes with advanced biliary tract cancer to observe their response against a new treatment that combines durvalumab with cisplatin and gemcitabine.
The growing demand for personalized medicine worldwide is driving the global market for cancer microbiome further. The increasing number of research and development activities and increasing collaborations between the microbiome industry and academia to utilize the resources and expertise of both are likely to add significant growth to the overall global cancer microbiome market share.
In addition, increasing collaboration between key players and innovative companies to develop transformative advancements is also expected to drive the market growth. For example, The University of Texas MD Anderson Cancer Centre and Federation Bio have partnered to create a synthetic microbial consortium, which aims to expand the number of cancer patients responding to immunotherapy.
Key biotech companies are also raising funds from investors interested in the development of new cancer treatments with the help of microbiome potential. For instance, Enterome, a biotech company, aims to raise USD 108 million for its clinical studies and support clinical trials, including two Phase II studies.
Pragma Bio has also raised a whopping USD 10 million in funding. The startup aims to initiate the first part of a 10-year plan. Pragma is using artificial intelligence to create a statistical model that identifies potential candidates for microbiome investigation. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with the microbiome. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with microbiome.
Global Cancer Microbiome Market Segmentations
Cancer Microbiome Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Products
- Services
- Hospitals
- Diagnostic Labs
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The increasing prevalence of chronic cancers across the globe is a major factor driving the growth of the market. The increasing demand for personalized cancer treatments is also influencing the market growth. The increasing use of genome sequencing in exploring the potential of microbiome in cancer treatments, as it helps researchers to analyze the composition of microbial communities in and around cancerous tissues, is also expected to drive the market growth. The continuous advancements in research and development activities also act as a major factor driving the global cancer microbiome market growth.
The market development is also driven by the heavy investments by pharmaceutical companies, government agencies, and private investors, in microbiome research for cancer and the development of new therapies and products. The increased number of clinical trials to explore and create microbiome-based treatments for cancer is gaining popularity in the market, further propelling the market growth.
Global Cancer Microbiome Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novogene Corporation
- Psomagen
- PerkinElmer Genomics
- Illumina
- Thermo Fisher Scientific
- Viome
- Invivo Healthcare
- Zymo Research Corp
- Metabiomics
- CD Genomics
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Cancer Microbiome Overview
- 3.1 Guidelines and stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Cancer Microbiome Epidemiology Analysis
- 5.1 Epidemiology Overview (2018-2034)
- 5.2 North America Cancer Microbiome Epidemiology (2018-2034)
- 5.3 Europe Cancer Microbiome Epidemiology (2018-2034)
- 5.4 Asia-Pacific Cancer Microbiome Epidemiology (2018-2034)
- 5.5 Latin America Cancer Microbiome Epidemiology (2018-2034)
- 5.6 Middle East & Africa Cancer Microbiome Epidemiology (2018-2034)
- 6 Global Cancer Microbiome Market Overview
- 6.1 Global Cancer Microbiome Market Historical Value (2018-2024)
- 6.2 Global Cancer Microbiome Market Forecast Value (2025-2034)
- 7 Global Cancer Microbiome Market Landscape
- 7.1 Cancer Microbiome: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Cancer Microbiome: Product Landscape
- 7.2.1 Analysis by Type
- 7.2.2 Analysis by End User
- 8 Global Cancer Microbiome Market Dynamics
- 8.1 Market Drivers and Constraints
- 8.2 SWOT Analysis
- 8.3 Porter’s Five Forces Model
- 8.4 Key Demand Indicators
- 8.5 Key Price Indicators
- 8.6 Industry Events, Initiatives, and Trends
- 8.7 Value Chain Analysis
- 9 Global Cancer Microbiome Market Segmentation
- 9.1 Global Cancer Microbiome Market by Type
- 9.1.1 Market Overview
- 9.1.2 Products
- 9.1.3 Services
- 9.2 Global Cancer Microbiome Market by End User
- 9.2.1 Market Overview
- 9.2.2 Hospitals
- 9.2.3 Diagnostic Labs
- 9.3 Global Cancer Microbiome Market by Region
- 9.3.1 Market Overview
- 9.3.2 North America
- 9.3.3 Europe
- 9.3.4 Asia Pacific
- 9.3.5 Latin America
- 9.3.6 Middle East and Africa
- 10 North America Cancer Microbiome Market
- 10.1 Market Share by Country
- 10.2 United States of America
- 10.3 Canada
- 11 Europe Cancer Microbiome Market
- 11.1 Market Share by Country
- 11.2 United Kingdom
- 11.3 Germany
- 11.4 France
- 11.5 Italy
- 11.6 Others
- 12 Asia Pacific Cancer Microbiome Market
- 12.1 Market Share by Country
- 12.2 China
- 12.3 Japan
- 12.4 India
- 12.5 ASEAN
- 12.6 Australia
- 12.7 Others
- 13 Latin America Cancer Microbiome Market
- 13.1 Market Share by Country
- 13.2 Brazil
- 13.3 Argentina
- 13.4 Mexico
- 13.5 Others
- 14 Middle East and Africa Cancer Microbiome Market
- 14.1 Market Share by Country
- 14.2 Saudi Arabia
- 14.3 United Arab Emirates
- 14.4 Nigeria
- 14.5 South Africa
- 14.6 Others
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 INDIA CDSCO
- 15.1.4 JAPAN PMDA
- 15.1.5 Others
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnership and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Novogene Corporation
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 Psomagen
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 PerkinElmer Genomics
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 Illlumina
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Thermo Fisher Scientific
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Viome
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Invivo Healthcare
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Zymo Research Corp
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Metabiomics
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 CD Genomics
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
